AtriCure Inc (ATRC)

23.91
NASDAQ : Health Care
Prev Close 23.33
Day Low/High 23.11 / 23.94
52 Wk Low/High 13.45 / 23.95
Avg Volume 166.00K
Exchange NASDAQ
Shares Outstanding 33.95M
Market Cap 791.97M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASYS, ATRC, LMIA, MSB, MT, PCOM, SPAR, SVM, TRUE Downgrades: AEL, ASH, ASPS, IMAX, INFN, JCP Initiations: EDIT Read on to get TheStreet Quant Ratings' detailed report:

AtriCure Reports First Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2017 financial results.

AtriCure Reaches Analyst Target Price

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $20.75, changing hands for $20.89/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip ® Left...

AtriCure To Announce First Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2017 financial...

AtriCure Names Two New Members To Its Board Of Directors

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves and B.

AtriCure Names National Principal Investigator For The CONVERGE IDE Clinical Trial

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr.

AtriCure To Present At The Needham & Company's 16th Annual Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company's 16 th...

AtriCure Announces Hiring Of Senior Vice President Of Clinical, Regulatory, And Scientific Affairs

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Vinayak (Vini) Doraiswamy, PhD as its Senior Vice...

AtriCure Reports Fourth Quarter And Full Year 2016 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full year 2016 financial results.

AtriCure Announces Preliminary Results For Fourth Quarter And Full Year 2016

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and...

AtriCure To Present At The Leerink Partners Global Healthcare Conference

AtriCure To Present At The Leerink Partners Global Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Leerink Partners Global...

Oversold Conditions For AtriCure (ATRC)

Oversold Conditions For AtriCure (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Announces Preliminary Results For Fourth Quarter And Full Year 2016

AtriCure Announces Preliminary Results For Fourth Quarter And Full Year 2016

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and...

AtriCure To Present At The 35th Annual JP Morgan Healthcare Conference

AtriCure To Present At The 35th Annual JP Morgan Healthcare Conference

AtriCure, Inc. ( Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 35 th Annual JP Morgan...

AtriCure Reaches Analyst Target Price

AtriCure Reaches Analyst Target Price

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $19.20, changing hands for $19.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure Names Sven Wehrwein To Its Board Of Directors

AtriCure Names Sven Wehrwein To Its Board Of Directors

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Sven Wehrwein has been appointed to its Board of...

AtriCure To Present At The Piper Jaffray 28th Annual Healthcare Conference

AtriCure To Present At The Piper Jaffray 28th Annual Healthcare Conference

AtriCure, Inc. ( Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 28 th Annual...

AtriCure Announces Approval For The CryoICE™ Platform In Japan

AtriCure Announces Approval For The CryoICE™ Platform In Japan

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of...

AtriCure Reports Third Quarter 2016 Financial Results

AtriCure Reports Third Quarter 2016 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2016 financial results.

AtriCure Announces Upcoming Investor Conference Schedule

AtriCure Announces Upcoming Investor Conference Schedule

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel Healthcare Conference at the...

AtriCure To Announce Third Quarter 2016 Financial Results

AtriCure To Announce Third Quarter 2016 Financial Results

AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the third quarter of 2016 on Thursday, October 27,...

Commit To Purchase AtriCure At $12.50, Earn 10.2% Annualized Using Options

Commit To Purchase AtriCure At $12.50, Earn 10.2% Annualized Using Options

Investors eyeing a purchase of AtriCure Inc stock, but cautious about paying the going market price of $15.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2017 put at the $12.50 strike, which has a bid at the time of this writing of 70 cents.

AtriCure To Present At The Morgan Stanley Global Healthcare Conference

AtriCure To Present At The Morgan Stanley Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare...

AtriCure Reports Second Quarter 2016 Financial Results

AtriCure Reports Second Quarter 2016 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2016 financial results.

AtriCure To Present At The Canaccord Genuity Growth Conference

AtriCure To Present At The Canaccord Genuity Growth Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Canaccord Genuity Growth Conference at the...

AtriCure To Announce Second Quarter 2016 Financial Results

AtriCure To Announce Second Quarter 2016 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the second quarter of 2016 on Thursday, August 4,...

AtriCure Receives CE Mark For The AtriClip® PRO2 Device

AtriCure Receives CE Mark For The AtriClip® PRO2 Device

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left Atrial...